The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Furthering cell therapy ambition across oncology and autoimmune diseases
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
This acquisition marks Max Healthcare's entry into Lucknow
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Subscribe To Our Newsletter & Stay Updated
